MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
Ofra Novoplansky(Ben-Gurion University of the Negev), Moshe Elkabets(Ben-Gurion University of the Negev)
Cited by 31
Related Papers
Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
|Science Signaling|2014|166
Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor of PKCs
|Proceedings of the National Academy of Sciences|2021|55
Activation of the <scp>EGFR</scp> / <scp>PI3K</scp> / <scp>AKT</scp> pathway limits the efficacy of trametinib treatment in head and neck cancer
|Molecular Oncology|2023|33
Enhanced ZnR/GPR39 Activity in Breast Cancer, an Alternative Trigger of Signaling Leading to Cell Growth
|Scientific Reports|2018|20